Ninnion CEO and Founder, Jeremy Caudill, is a two-time stroke survivor. A significant body of research now confirms that sub-psychedelic doses of a 5-HT2A agonist promote neurogenesis and synaptogenesis and reduce the production of inflammatory cytokines. These activities hold promise for the use of 5-HT2A agonists to promote brain remodeling in recovery from stroke and other brain injuries. Ninnion is developing NIN-S119, an orally-available 5-HT2A agonist, for outpatient administration in stroke recovery. Dr. Bill Massey, Ninnion’s Chief Development Officer, discusses the company’s NIN-S119 Ischemic Stroke development program and its potential to revolutionize treatment for stroke recovery.